From Investor’s Business Daily: 2024-05-14 13:47:00

Vertex Pharmaceuticals stock (VRTX) continues near its all-time high, with a rising Relative Strength Rating now at 72, surpassing 72% of all stocks. The company focuses on drugs for cystic fibrosis, sickle cell disease, and beta thalassemia, with impressive ratings, including a top 3% Composite Rating and A SMR Rating.

Vertex stock is attempting a cup without handle pattern with a 448.40 buy point. Recent quarters show strong sales and profit growth, with a 56% surge in earnings to $4.76 per share and 13% higher revenue to $2.69 billion. The stock ranks No. 3 in its industry group, with solid top-line growth.

The unique IBD Relative Strength Rating, comparing a stock’s price performance to others, highlights Vertex’s technical strength and potential. Consider monitoring Vertex’s performance as it continues to rise and potentially break out from its consolidation phase.



Read more at Investor’s Business Daily: Vertex Stock Hit All-Time High, Rising Again